Skip to content

Gene Editing to Cure Cancer

After the discovery of CRISPR in bacteria, a cut and paste DNA system used to defend against foreign genetic sequences especially those inserted by viruses, researchers transformed the discovery into a tool called CRISPR/Cas9 that can make precise cuts in the genomes of other organisms as well.

To put this tool to good use, researchers at the University of Pennsylvania have proposed a clinical trial where this gene editing technology would remove and alter human T cells that target foreign cells in cancer patients.

Since clinical trials of gene-editing therapies have already taken place and the ethical considerations have already been discussed, the researchers have cleared the first hurdle by winning unanimous approval from the Recombinant DNA Advisory Committee at the U.S. National Institutes of Health.

The proposed two-year trial will treat 18 people with myeloma, sarcoma, or melanoma who have stopped responding to existing treatments at U Penn; the University of California, San Francisco; and the University of Texas MD Anderson Cancer Center in Houston. For the next step, the researchers will need to obtain approval from the ethics review boards at their institutions and the U.S. Food and Drug Administration.

So far, the testing of the CRISPR/Cas9 system in lab animals has yielded mixed results and worked only on some cancers. However, the researchers have made improvements to the technology and will monitor immune responses and for any off-target cuts in genomes.

As Hank Greely, a Stanford law professor points out, whoever owns the therapies stand to make a lot of money. Currently there are potential financial conflicts of interest and issues with intellectual property. The Parker Institute, a foundation established by Facebook billionaire Sean Parker, is funding the trials. The trials will utilize methods based upon earlier work by Carl June of U Penn, which genetically modified cancer patients’ immune cells and would create a financial interest in the outcome.   

Researchers at the University of California, Berkeley, filed a patent application in 2012. Then, researchers at the Broad Institute of MIT and Harvard filed a patent application under an expedited review program and were awarded the patent in April 2014. Until recently, the US awarded patents to those who could show that they were the first to invent, rather than the first to file. Then US switched to a first-to-file system, complicating things, and now proper licensing agreements have to be established.

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

More To Explore

Emerging Technologies

Mis/DisInformation

Executive Overview You would think we should have been enlightened by the past few decades of the Knowledge Age, so why do people seem badly

Expert

Ian Browde, USA

  PROFILE SUMMARY My experience includes human/machine interface design for leveraging computers for personal growth, see U.S. Patent #7574415, cybersecurity and cyber-physical security and safety.

Thanks for subscribing to our newsletter, Bill’s Blog.

We suggest you place our address in your approved email list.
Look for your first issue soon.
The TechCast Team